WO2015175008A8 - Methods of treating chronic kidney disease characterized by macroalbuminuria - Google Patents

Methods of treating chronic kidney disease characterized by macroalbuminuria Download PDF

Info

Publication number
WO2015175008A8
WO2015175008A8 PCT/US2014/046348 US2014046348W WO2015175008A8 WO 2015175008 A8 WO2015175008 A8 WO 2015175008A8 US 2014046348 W US2014046348 W US 2014046348W WO 2015175008 A8 WO2015175008 A8 WO 2015175008A8
Authority
WO
WIPO (PCT)
Prior art keywords
macroalbuminuria
kidney disease
chronic kidney
treating chronic
methods
Prior art date
Application number
PCT/US2014/046348
Other languages
French (fr)
Other versions
WO2015175008A1 (en
Inventor
Philip B. Graham
Original Assignee
Concert Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals, Inc. filed Critical Concert Pharmaceuticals, Inc.
Publication of WO2015175008A1 publication Critical patent/WO2015175008A1/en
Publication of WO2015175008A8 publication Critical patent/WO2015175008A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention relates to a novel method of treating chronic kidney disease in patient with macroalbuminuria. The method comprises administering to the patient an effective amount of a compound described herein.
PCT/US2014/046348 2014-05-14 2014-07-11 Methods of treating chronic kidney disease characterized by macroalbuminuria WO2015175008A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461993093P 2014-05-14 2014-05-14
US61/993,093 2014-05-14

Publications (2)

Publication Number Publication Date
WO2015175008A1 WO2015175008A1 (en) 2015-11-19
WO2015175008A8 true WO2015175008A8 (en) 2016-01-28

Family

ID=51298953

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/046348 WO2015175008A1 (en) 2014-05-14 2014-07-11 Methods of treating chronic kidney disease characterized by macroalbuminuria

Country Status (1)

Country Link
WO (1) WO2015175008A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2265334A2 (en) * 2008-02-29 2010-12-29 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US20110053961A1 (en) * 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US8263601B2 (en) * 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
WO2013013052A1 (en) * 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives

Also Published As

Publication number Publication date
WO2015175008A1 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
EA033286B1 (en) Method of treating or delaying the progression of chronic kidney disease
EP3122414A4 (en) Venous disease treatment
PH12015502075A1 (en) Treatment of cataplexy
WO2016044189A8 (en) Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists
WO2015081085A3 (en) Methods of treating a tauopathy
WO2015023976A3 (en) Selective grp94 inhibitors and uses thereof
EP3261713A4 (en) Blood pump for treatment of bradycardia
EP2967049A4 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
WO2016094834A3 (en) A method for treating a complement mediated disorder caused by an infectious agent in a patient
MX2016003823A (en) A selective inhibitor of phosphatidylinositol 3-kinase-gamma.
WO2016089886A3 (en) Methods for treating dry eye disease by administering an il-6r antagonist
WO2013101451A8 (en) Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
CA2909956C (en) Accelerated healing of eye injuries by angiotensin peptides
BR112018003526A2 (en) methods of treating inflammatory diseases
IL259755B (en) Methods for the treatment of bees by administration of cannabinoids
WO2015138532A3 (en) Methods for the treatment of kidney fibrosis
EA201891342A1 (en) Isoindole compounds
WO2017019540A3 (en) Inhibitors of n-linked glycosylation and methods using same
WO2014160281A3 (en) Method of enhancing delivery of therapeutic compounds to the eye
WO2016057683A3 (en) Novel anti-nodal antibodies and methods of using same
WO2016094899A3 (en) Treatment of hmgb1-mediated inflammation
NZ722600A (en) Methods of treating mild brain injury
NZ730092A (en) Use of cysteamine in treating infections caused by yeasts/moulds
WO2015080980A3 (en) Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators
WO2015023508A8 (en) Methods for improving asthma symptoms using benralizumab

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14748348

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14748348

Country of ref document: EP

Kind code of ref document: A1